Tag Archives: Ritu Baral
Cowen & Co. Maintains Their Buy Rating on Sarepta Therapeutics (SRPT)
Cowen & Co. analyst Ritu Baral maintained a Buy rating on Sarepta Therapeutics (SRPT – Research Report) today and set a price target of $213.00. The company’s shares closed last Monday at $124.63. According to TipRanks.com, Baral is a 5-star
Cowen & Co. Remains a Buy on ACADIA Pharmaceuticals (ACAD)
Cowen & Co. analyst Ritu Baral maintained a Buy rating on ACADIA Pharmaceuticals (ACAD – Research Report) today and set a price target of $66.00. The company’s shares closed last Monday at $41.80. According to TipRanks.com, Baral is a 5-star
Insmed (INSM) Gets a Buy Rating from Cowen & Co.
Cowen & Co. analyst Ritu Baral maintained a Buy rating on Insmed (INSM – Research Report) yesterday and set a price target of $56.00. The company’s shares closed last Monday at $23.91. According to TipRanks.com, Baral is a 5-star analyst
Sangamo Biosciences (SGMO) Receives a Rating Update from a Top Analyst
Cowen & Co. analyst Ritu Baral maintained a Buy rating on Sangamo Biosciences (SGMO – Research Report) today. The company’s shares closed last Monday at $11.66. According to TipRanks.com, Baral is a top 100 analyst with an average return of
Cowen & Co. Keeps a Buy Rating on SAGE Therapeutics (SAGE)
Cowen & Co. analyst Ritu Baral maintained a Buy rating on SAGE Therapeutics (SAGE – Research Report) today and set a price target of $96.00. The company’s shares closed last Monday at $61.02, close to its 52-week low of $56.50.
ACADIA Pharmaceuticals (ACAD) Receives a Rating Update from a Top Analyst
In a report released today, Ritu Baral from Cowen & Co. maintained a Buy rating on ACADIA Pharmaceuticals (ACAD – Research Report), with a price target of $66.00. The company’s shares closed last Monday at $44.28, close to its 52-week
